Q-omics provides the consensus-scored CYCSP38 profile across patient tissues and cancer cell-line models. CYCSP38 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CYCSP38 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, CYCSP38 RNA expression shows 10,948 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight MESO, KIRC, and LAML as cancer lineages where CYCSP38 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYCSP38 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYCSP38 survival associations across molecular data types. CYCSP38 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYCSP38 RNA expression–survival associations across cancer types. High CYCSP38 expression shows unfavorable associations in MESO, THCA, READ and ESCA, but favorable associations in UCS and SKCM. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for CYCSP38 RNA expression.
This table summarizes CYCSP38 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CYCSP38. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYCSP38 shows lower tumor expression in KIRC, THCA, COAD and KIRP and higher tumor expression in BLCA and BRCA. The KIRC box plot shows higher CYCSP38 RNA expression in normal versus tumor tissue (log2 FC = −0.173, t-test p < 0.001).
This table shows molecular features associated with CYCSP38 in patient tissues and cancer cell lines. In patient samples, CYCSP38 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
